Answers are grounded in this paper and cite their sources.
Percutaneous cholecystostomy (PC) is an option to manage acute cholecystitis (AC) in high-risk patients for cholecystectomy. Data on PC use in patients with liver cirrhosis are lacking. We used the National Inpatient Sample database to extract a retrospective cohort (October 2015–December 2019) of cirrhosis hospitalizations. Those with AC receiving PC were matched to those not receiving PC. Inhospital mortality (IHM), length of stay in days, total charges in United States Dollar, and liver disease complications were outcomes. Of 754,245 hospitalizations with cirrhosis, 2989 (0.4%) had AC with no change over time, P = .13. Of AC hospitalizations, 456 (15.3%) received PC, with no change over time, P = .845. In a propensity-matched cohort of 1335 hospitalizations (445 PC), PC was associated with higher IHM (33 vs 10.9%), mean length of stay (13.5 vs 8.5 days), total charges (174,264 vs 117,957 United States Dollar), acute kidney injury (47.4 vs 32.6%), and sepsis (40.9 vs 19.2%), P < .01 for all. In a conditional logistic model, hospitalizations with versus without PC were associated with 2-fold IHM (1.88; 1.37–2.59). One in six AC hospitalizations is managed with PC, which is associated with morbidity, use of hospital resources, and patient mortality. Prospective studies are needed to identify cirrhosis patients with AC likely to benefit from PC.
No takes yet. Share an insight, caveat, or question.
Awadalla et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: